# US 2014/0057830 A1 · Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0057830 A1
- Document ID: US20140057830A1
- Status: Published application
- Kind: A1
- Application number: 13/994,107
- Filed: 2012-01-06
- Published: 2014-02-27
- Earliest claimed: 2011-01-06
- Assignees: Complix NV
- Inventors: Ignace Lasters; Johan Desmet; Maria Henderikx; Anita Wehnert; Geert Meersseman
- Web page: https://patentgrep.com/patent/US20140057830A1

## CPC

- C07K 14/001: {by chemical synthesis}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Alphabodies that specifically bind to cytokines or growth factor and/or their receptors, as well as polypeptides that comprise or essentially consist of such Alphabodies. Further nucleic acids encoding such Alphabodies; methods for preparing such Alphabodies and polypeptides; host cells expressing or capable of expressing such Alphabodies and polypeptides; compositions, and in particular pharmaceutical compositions, that comprise such Alphabodies, polypeptides, nucleic acids and/or host cells; and uses of such Alphabodies or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

## Claims

### Claim 1

An Alphabody polypeptide comprising an Alphabody, which specifically binds to a member of a cytokine-cytokine receptor or growth factor-growth factor receptor complex.

### Claim 2 (depends on 1)

The Alphabody polypeptide according to claim 1, which is characterized in that the binding
site is located primarily either
on the helix surface of the Alphabody,
in a groove of the Alphabody, involving at least one e or g residue of the Alphabody helix
in the loop or linker region of the Alphabody.

### Claim 3 (depends on 1)

The Alphabody polypeptide according to claim 1, wherein the binding site is formed primarily either:
(i) by heptad e-positions in a first alpha-helix of the Alphabody and by heptad g-positions in a second alpha-helix, and optionally by heptad b-positions in said first alpha-helix of the Alphabody and/or by heptad c-positions in said second alpha-helix of the Alphabody, or
(ii) by heptad b-, c- and f-positions in one alpha-helix of the Alphabody, or
(iii) by positions in a linker fragment connecting two consecutive alpha-helices of the Alphabody.

### Claim 4 (depends on 1)

The Alphabody polypeptide according to claim 1, which specifically binds to a cytokine or growth factor.

### Claim 5 (depends on 4)

The Alphabody polypeptide according to claim 4, which specifically binds to the receptor binding site on said cytokine or growth factor.

### Claim 6 (depends on 1)

The Alphabody polypeptide according to claim 1, which specifically binds to a cytokine receptor or growth factor receptor.

### Claim 7 (depends on 6)

The Alphabody polypeptide according to claim 6, wherein said Alphabody polypeptide specifically binds to the cytokine or growth factor binding site on said cytokine receptor or growth factor receptor.

### Claim 8 (depends on 1)

The Alphabody polypeptide according to claim 1, wherein said Alphabody polypeptide inhibits the interaction between a cytokine or growth factor and a cytokine receptor or growth factor receptor.

### Claim 9 (depends on 1)

The Alphabody polypeptide according to claim 1, wherein said Alphabody polypeptide specifically binds to said cytokine or growth factor and/or to said cytokine receptor or growth factor receptor with a dissociation constant (KD) of at least 1 micromolar.

### Claim 10 (depends on 4)

The Alphabody polypeptide according to claim 4, wherein said cytokine or growth factor is chosen from the group consisting of cardiotrophin 1, cardiotrophin-like cytokine factor 1, ciliary neurotrophic factor, interleukin 11, interleukin 6 (interferon, beta 2), leukemia inhibitory factor (cholinergic differentiation factor), oncostatin M, interleukin 13, interleukin 12A, interleukin 23 alpha subunit p19, colony stimulating factor 2, interleukin 3, interleukin 5, interleukin 2, interleukin 4 isoform 1, interleukin 7, interleukin 9, interleukin 15 preproprotein, interleukin 21, colony stimulating factor 3 isoform a, erythropoietin, growth hormone 1 isoform 1, growth hormone 2 isoform 1, leptin, prolactin, thymic stromal lymphopoietin isoform 1, thyroid peroxidase isoform a, interleukin 1 alpha proprotein and interleukin 1 beta proprotein, interleukin 10, interleukin 19 isoform 2, interleukin 20, interleukin 22, interleukin 24 isoform 1, interleukin 28A, interleukin 28B, interleukin 29, interleukin 17, interleukin 17B, interleukin 17E isoform 1, interferon alpha 1, interferon beta 1, interferon kappa, interferon epsilon 1, interferon omega 1, interferon gamma, tumor necrosis factor ligand superfamily member 7, tumor necrosis factor ligand superfamily member 14 isoform 1 precursor, tumor necrosis factor ligand superfamily member 13 isoform alphaproprotein, tumor necrosis factor ligand superfamily, member 11 isoform 1, tumor necrosis factor alpha, tumor necrosis factor (ligand) superfamily member 9, tumor necrosis factor (ligand) superfamily member 8, tumor necrosis factor (ligand) superfamily member 4, tumor necrosis factor (ligand) superfamily member 18, tumor necrosis factor (ligand) superfamily member 13b, tumor necrosis factor (ligand) superfamily member 12 isoform 1 precursor, tumor necrosis factor (ligand) superfamily member 10, lymphotoxin-beta isoform a, lymphotoxin alpha, fas ligand, ectodysplasin A isoform EDA-A2, nerve growth factor, CD27 ligand, CD30 ligand, CD40 ligand, colony stimulating factor 1 isoform a, epidermal growth factor (beta-urogastrone), fms-related tyrosine kinase 3 ligand, hepatocyte growth factor isoform 1 preproprotein, KIT ligand isoform b, PH domain-containing protein, platelet-derived growth factor beta isoform 1 preproprotein, platelet-derived growth factor C, vascular endothelial growth factor B, vascular endothelial growth factor C preproprotein, vascular endothelial growth factor isoform a, transforming growth factor beta 3, transforming growth factor beta 2, transforming growth factor beta 1, inhibin beta C chain preproprotein, inhibin beta B subunit, inhibin beta A, growth differentiation factor 5 preproprotein, bone morphogenetic protein 7, bone morphogenetic protein 2, anti-Mullerian hormone, activin beta E, chemokine (C motif) ligand 1, chemokine (C motif) ligand 2, chemokine (C-C motif) ligand 14 isoform 1, chemokine (C-C motif) ligand 15, chemokine (C-C motif) ligand 20, chemokine (C-C motif) ligand 26, chemokine (C-C motif) ligand 3, chemokine (C-C motif) ligand 4, chemokine (C-C motif) ligand 7, chemokine (C-C motif) ligand 1, chemokine (C-C motif) ligand 11, chemokine (C-C motif) ligand 13, chemokine (C-C motif) ligand 16, chemokine (C-C motif) ligand 17, chemokine (C-C motif) ligand 19, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 21, chemokine (C-C motif) ligand 22, chemokine (CC motif) ligand 23 isoform CKbeta8-1, chemokine (C-C motif) ligand 24, chemokine (C-C motif) ligand 25 isoform 1, chemokine (C-C motif) ligand 27, chemokine (C-C motif) ligand 28, chemokine (C-C motif) ligand 5, chemokine (C-C motif) ligand 8, chemokine (C-X-C motif) ligand 1, chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)isoform beta, chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant), chemokine (C-X-C motif) ligand 16, chemokine (C-X-C motif) ligand 2, chemokine (C-X-C motif) ligand 3, chemokine (C-X-C motif) ligand 5, chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein2), interleukin 8, pro-platelet basic protein, platelet factor (PF)4, groa, MIG, ENA-78, macrophage inflammatory protein (MIP) I a, MIP I monocyte chemoattractant protein (MCP)-1, 1-3 09, HC 14, C 10, Regulated on Activation, Normal T-cell Expressed, Secreted (RANTES), chemokine (C-X-C motif) ligand 10, chemokine (C-X-C motif) ligand 11, chemokine (C-X-C motif) ligand 9 and chemokine (C-X3-C motif) ligand 1.

### Claim 11 (depends on 6)

The Alphabody polypeptide according to claim 6, wherein said cytokine or growth factor receptor is chosen from the group consisting of type 1 interleukin receptor, erythropoietin receptor, GM-CSF receptor, G-CSF receptor, growth hormone receptor, prolactin receptor, oncostatin M receptor, leukemia inhibitory factor receptor, type II interleukin receptors, interferon-alpha/beta receptor, interferon-gamma receptor, interleukin-1 receptor, CSF1, C-kit receptor, interleukin-18 receptor, CD27, CD30, CD120, CD40, lymphotoxin beta receptor, interleukin-8 receptor, CCR1, CCR5, CXCR4, CXCR7, MCAF receptor, NAP-2 receptor, CC chemokine receptors, CXC chemokine receptors, CX3C chemokine receptors, XC chemokine receptor (XCR1), TGF beta receptor 1 and TGF beta receptor 2.

### Claim 12 (depends on 8)

The Alphabody polypeptide according to claim 8, wherein said cytokine or growth factor is a heterodimeric cytokine or growth factor and/or wherein said cytokine or growth factor receptor is a receptor for a heterodimeric cytokine or growth factor.

### Claim 13 (depends on 12)

The Alphabody polypeptide according to claim 12, wherein said heterodimeric cytokine is chosen from the group consisting of IL-12, IL-23, IL-27 and IL-35 and/or said receptor for a heterodimeric cytokine is chosen from the group consisting of IL-12 receptor, the IL-23 receptor, the IL-27 receptor and the IL-35 receptor.

### Claim 14 (depends on 12)

The Alphabody polypeptide according to claim 12, wherein said heterodimeric cytokine is IL-23.

### Claim 15 (depends on 14)

The Alphabody polypeptide according claim 14, wherein said Alphabody polypeptide binds to the p19 subunit of IL-23.

### Claim 16 (depends on 13)

The Alphabody polypeptide according to claim 13, wherein said Alphabody polypeptide binds to the p19 subunit and not to the p40 subunit of IL-23.

### Claim 17 (depends on 1)

The Alphabody polypeptide according to claim 1 having at least 80% sequence identity with at least one of the amino acid sequences corresponding to any one of SEQ ID NO: 1 to SEQ ID NO: 127 and SEQ ID NO: 134 and SEQ ID NO: 135.

### Claim 18 (depends on 1)

The Alphabody polypeptide according to claim 1, wherein said Alphabody polypeptide binds to Flt3 ligand or Flt3 receptor.

### Claim 19 (depends on 1)

The Alphabody polypeptide according to claim 1, optionally comprising, in addition to said Alphabody one or more further groups, optionally linked via one or more linkers.

### Claim 20 (depends on 1)

Nucleic acid sequence encoding an Alphabody polypeptide according to claim 1.

### Claim 21 (depends on 1)

Pharmaceutical composition comprising at least one Alphabody polypeptide according to claim 1 and optionally at least one pharmaceutically acceptable carrier.

### Claim 22

A method for the production of at least one Alphabody polypeptide having detectable binding affinity for a cytokine or growth factor and/or for a receptor of said cytokine or growth factor, said method at least comprising the steps of:
a) producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% of said variegated amino acid residue positions are located either:
(i) at heptad e-positions in a first alpha-helix of the Alphabody polypeptides and at heptad g-positions in a second alpha-helix, and optionally at heptad b-positions in said first alpha-helix of the Alphabody polypeptides and/or at heptad c-positions in said second alpha-helix of the Alphabody polypeptides, or
(ii) at heptad b-, c- and f-positions in one alpha-helix of the Alphabody polypeptides, or
(iii) at positions in a linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides, and
b) selecting from said single-chain Alphabody library at least one single-chain Alphabody polypeptide having detectable binding affinity for said cytokine or growth factor and/or for a receptor of said cytokine or growth factor.

### Claim 23 (depends on 1)

A method of treatment for a patient suffering from an inflammatory and/or auto-immune disease, transplant rejection, cystic fibrosis, asthma, chronic obstructive pulmonary disease, cancer, viral infection, or common variable immunodeficiency, comprising the administration of an effective amount of an Alphabody polypeptide specifically binding to a cytokine or growth factor and/or a cytokine receptor or growth factor receptor according to claim 1.
